CPRX News and Press, Catalyst Pharmaceuticals Inc. From 08/09/23

2023-08-09 16:23:21 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.53 beats by $0.24 . Revenue of $99.58M (+87.5% Y/Y) beats by $7.87M . Achieved all-time high total revenues of $99.6 million for Q2 2023, an 87.5% YoY increase...

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE ® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter N...

2023-08-08 17:35:58 ET Catalyst Pharmaceuticals ( NASDAQ: CPRX ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, after market close. The consensus EPS Estimate is $0.29 (+3.6% Y/Y) and the consensus Revenue Estimate is $91.71M (+72.7% Y/Y). Over ...

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ...

CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that...

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters Catalyst's Rare Neuroscience Portfolio Granted FDA Fast Track, Orphan Drug Designation, an...

2023-07-04 21:39:50 ET Summary The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may ...

2023-07-03 10:02:15 ET Summary This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will re...

2023-07-03 06:49:30 ET Summary We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic...

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Treat Duchenne Muscular Dystrophy Catalyst Exp...